2-(4-甲基哌嗪)-1-苯基乙胺 | 775349-54-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-(4-甲基哌嗪)-1-苯基乙胺
• 中文别名: 2-(4-甲基哌嗪-1-基)-1-苯基乙烷-1-胺
• 英文名称: 2-(4-methylpiperazin-1-yl)-1-phenylethan-1-amine
• 英文别名: 2-(4-methylpiperazinyl)-1-phenylethylamine；2-(4-methylpiperazin-1-yl)-1-phenylethanamine
• CAS: 775349-54-7
• 化学式: C₁₃H₂₁N₃
• mdl: MFCD01862534
• 分子量: 219.33
• InChiKey: UXNGEVJNOQJIJW-UHFFFAOYSA-N

物化性质

• 沸点：
  334.9±32.0 °C(Predicted)
• 密度：
  1.038±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  2-(4-甲基哌嗪)-1-苯基乙胺 在 palladium diacetate 、 potassium carbonate 、 N,N-二异丙基乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 、 异丙醇 为溶剂， 反应 5.0h， 生成 6-N-(5-cyclopropyl-1H-pyrazol-3-yl)-4-N-[2-(4-methylpiperazin-1-yl)-1-phenylethyl]pyrimidine-4,6-diamine
  参考文献：
  名称：

  TRK INHIBITION

  摘要：

  本发明涉及使用取代吡唑衍生物来调节肌浆膜相关激酶（Trk）家族蛋白激酶，并且使用这些取代吡唑衍生物来治疗疼痛、炎症、癌症、再狭窄、动脉粥样硬化、银屑病、血栓形成、与失髓鞘或脱髓鞘有关的疾病、紊乱、损伤或功能障碍，或与神经生长因子（NGF）受体TrkA异常活动相关的疾病或紊乱。

  公开号：

  US20180346450A1

文献信息

• [EN] SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS<br/>[FR] TÉTRAHYDROAZOLOPYRAZINES SULFONYLÉES ET LEUR UTILISATION EN TANT QUE PRODUITS MÉDICAMENTEUX
  申请人：GRUENENTHAL GMBH

  公开号：WO2010099938A1

  公开（公告）日：2010-09-10

  The present invention relates to sulfonylated tetrahydroazolopyrazines, methods for the preparation thereof, medicinal products containing these compounds and the use of substituted indole compounds for the preparation of medicinal products (Formula I).

  本发明涉及磺酰化四氢咯啉吡嗪，其制备方法，含有这些化合物的药物产品以及用于制备药物产品的取代吲哚化合物的使用（式I）。
• NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF
  申请人：VIVOZON, INC.

  公开号：US20140336378A1

  公开（公告）日：2014-11-13

  Disclosed are a novel benzamide derivative and pharmaceutical use thereof, and more particularly, a novel benzamide derivative having a structure of Formula 1 or pharmaceutically acceptable salts thereof, and a composition for prevention or treatment of pain or itching including the above material. The novel benzamide derivative and pharmaceutically acceptable salt thereof according to the present invention exhibit excellent pain-suppressive effect and, in particular, pain-suppressive effect in not only a neuropathic animal model but also other models such as a formalin model, and therefore, may be used in suppression of different pains such as nociceptive pain, chronic pain, etc. Further, since it was demonstrated that the present invention displays anti-pruritic efficacy even in an itching model, to which a mechanism and treatment concept established with respect to pain is applied, the present invention may also be effectively used in radical treatment of atopic dermatitis by applying the inventive product to an anti-pruritic composition in order to suppress an initial itching stage and treat symptoms thereof, thus preventing skin damage or inflammation after the scratching stage.

  揭示了一种新的苯甲酰胺衍生物及其药用，更具体地说，一种具有化学式1结构或其药用盐的新苯甲酰胺衍生物，以及包括上述材料的用于预防或治疗疼痛或瘙痒的组合物。根据本发明，所述新的苯甲酰胺衍生物及其药用盐表现出优异的镇痛效果，特别是在不仅神经病理动物模型中而且其他模型如福尔马林模型中表现出的镇痛效果，因此，可用于抑制不同类型的疼痛，如伤害性疼痛、慢性疼痛等。此外，由于证明了本发明在瘙痒模型中显示出抗瘙痒功效，应用于疼痛方面建立的机制和治疗概念，因此，本发明还可通过将创新产品应用于抗瘙痒组合物中，以抑制初始瘙痒阶段并治疗其症状，从而预防刮痒阶段后的皮肤损伤或炎症。
• [EN] DPP-IV INHIBITORS<br/>[FR] INHIBITEURS DE LA DPP-IV
  申请人：GRAFFINITY PHARMACEUTICALS AG

  公开号：WO2005095343A1

  公开（公告）日：2005-10-13

  The invention relates to compounds of formula (I), Z-C(R<1>R<2>)-C(R<3>NH2)-C(R<4>R<5>)-X-N(R<6>R<7>), wherein Z, R<1-7> and X have the meaning as cited in the description and the claims. Said compounds are useful as DPP-lV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  该发明涉及式(I)的化合物，其中Z-C(R1R2)-C(R3NH2)-C(R4R5)-X-N(R6R7)，其中Z，R1-7和X的含义如描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备此类化合物以及其作为药物的生产和使用。
• 2,2,2-Trifluoroethyl Oxalates in the One-Pot Parallel Synthesis of Hindered Aliphatic Oxamides
  作者：Andrey V. Bogolubsky、Yurii S. Moroz、Pavel K. Mykhailiuk、Sergey E. Pipko、Alexander V. Grishchenko、Anton V. Zhemera、Anzhelika I. Konovets、Roman A. Doroschuk、Yurii V. Dmytriv、Olga A. Zaporozhets、Andrey Tolmachev

  DOI：10.1002/ejoc.201501579

  日期：2016.4

  A simple parallel synthesis approach to unsymmetrical N1,N2-substituted aliphatic oxamides using methyl (2,2,2-trifluoroethyl) oxalate and bis(2,2,2-trifluoroethyl) oxalate was developed. The method was validated on a 52-membered set of the oxamides, derived mainly from hindered primary and secondary aliphatic amines, and gave the products with a high overall success rate in moderate yields.

  开发了一种使用草酸甲酯 (2,2,2-三氟乙基) 和草酸双 (2,2,2-三氟乙基) 酯合成不对称 N1,N2 取代脂肪族草酰胺的简单平行合成方法。该方法在 52 元草酰胺组上进行了验证，草酰胺主要来自受阻的伯胺和仲脂肪胺，并以中等产率获得了具有高总体成功率的产品。
• [EN] COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS<br/>[FR] COMPOSES ET COMPOSITIONS UTILISES COMME INHIBITEURS DE LA CATHEPSINE S
  申请人：NOVARTIS AG

  公开号：WO2006018284A1

  公开（公告）日：2006-02-23

  The present invention relates to the use of a 2-cyanopyrimidine compound of the formula (I), wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and , where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.

  本发明涉及使用式(I)的2-氰基嘧啶化合物，其中R1、R2、R3和X如规范和权利要求中定义的那样，以自由形式或盐形式，并在可能的情况下以互变异构形式，作为猫hepsin S活性的抑制剂。